Somatostatin Analogs Market, By Type (Octreotide, Lanreotide, Pasireotide), By Indication and By Region (North America, Europe, Asia Pacific and RoW) Analysis, Share, Trends, Size, & Forecast From 2014 2025
REPORT HIGHLIGHT
The Somatostatin Analogs market is estimated to represent a global market of USD 2.40 billion by 2017 with growth rate of 3.0%.
Market Dynamics
Somatostatin analogs are considered to be the first line of treatment in conditions such as carcinoid syndrome, acromegaly, Cushing syndrome and others. These analogues act by inhibiting production of growth hormones and serotonin. The global somatostatin analogs market is driven by an increasing incidence rate of acromegaly and neuroendocrine tumors. For instance, as per the CureResearch, the prevalence of acromegaly in China was estimated to over 50,000 and is expected to increase in future. Furthermore, rising awareness, training and education by Pituitary Association of Australia and UK & Ireland Neuroendocrine Tumour Society is likely to have positive impact on the industry growth. However, high costs associated with the treatment coupled with strict reimbursement policies is expected to hamper the growth. The huge investments involved in developing somatostatin products is also resulting in reduction in number of companies investing in this market, restraining the market growth to some extent.
Figure 1- Global Somatostatin Analogs Market Size, by Analog Type (2018 vs 2025)
Analog Type Takeaway
Within the analogs type segment, octreotide (sandostatin) accounted for highest market share. The market for octreotide was over USD 1.5 billion. The drug was marketed by Novaritis in North America, Europe and many other developing countries worldwide. The patent for octreotide (Sandostatin LAR) was expired in the U.S. (2014), resulting in generic competition. Rising popularity of Lanreotide (Somatuline) in the developed regions is anticipated to fuel the industry growth. Rising penetration coupled with the increasing usage of somatuline for carcinoid syndrome is projected to generate lucrative growth opportunity for this market in future. The neuroendocrine segment is expected to grow with a fastest CAGR owing to the rising incidence rate of neuroendocrine tumors.
Regional Takeaway
North America held 45% of market share. Growth of this region is majorly attributed to the rising cases of acromegaly and neuroendocrine tumor. In addition, rising awareness and increased accuracy of diagnosis in developed economies created a positive outlook for the acceptance of somatostatin analogs in the region. Furthermore, presence of favorable reimbursement schemes and increasing research and development activities establish healthy platform for this industry growth.
On contrary, Asia Pacific is expected to exhibit a fastest CAGR over the forecast period. Increased in research and development and launch of innovative formulation are the main factor driving the growth over the study period. For instance, Sun Pharma introduced somatostatin analogs product which can be indicated for the treatment of acromegaly.
Key Vendor Analysis
The global industry is consolidated in nature, where, few number of companies accounted for the significant revenue share. Companies namely IPSEN and Novartis AG dominated the global market with over 80% of revenue share. Novartis’s new product Signifor and Signifor LAR is gaining momentum in the U.S. and Europe countries. This product exhibits better affinity for somatostatin receptor 5 and also has longer half-life compared to octreotide which is anticipated to help the company in keeping its leading position in future.
The market size and forecast for each segment and sub-segments has been considered as below:
- Historical Year – 2014 & 2016
- Base Year – 2017
- Estimated Year – 2018
- Projected Year – 2025
TARGET AUDIENCE
- Traders, Distributors, and Suppliers
- Manufacturers
- Government and Regional Agencies
- Research Organizations
- Consultants
- Distributors
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
MARKET, BY ANALOG TYPE
- Octreotide
- Lanreotide
- Pasireotide
MARKET, BY INDICATION
- Acromegaly
- Neuroendocrine Tumor (NET)
- Others
MARKET, BY REGION
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- Rest of Europe
- Asia Pacific
- India
- China
- Rest of APAC
- Rest of the World
- Middle East and Africa
- Latin America
TABLE OF CONTENT
1. SOMATOSTATIN ANALOGS MARKET OVERVIEW
1.1. Study Scope
1.2. Assumption and Methodology
2. EXECUTIVE SUMMARY
2.1. Key Market Facts
2.2. Geographical Scenario
2.3. Companies in the Market
3. SOMATOSTATIN ANALOGS KEY MARKET TRENDS
3.1. Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Market Opportunities
3.4. Market Future Trends
4. SOMATOSTATIN ANALOGS INDUSTRY STUDY
4.1. Porter’s Analysis
4.2. Market Attractiveness Analysis
4.3. Regulatory Framework Analysis
5. SOMATOSTATIN ANALOGS MARKET LANDSCAPE
5.1. Market Share Analysis
6. SOMATOSTATIN ANALOGS MARKET – BY ANALOG TYPE
6.1. Overview
6.1.1. Overview
6.1.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
6.2. Octreotide
6.2.1. Overview
6.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
6.3. Lanreotide
6.3.1. Overview
6.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
6.4. Pasireotide
6.4.1. Overview
6.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
7. SOMATOSTATIN ANALOGS MARKET – BY INDICATION
7.1. Overview
7.1.1. Overview
7.1.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
7.2. Acromegaly
7.2.1. Overview
7.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
7.3. Neuroendocrine Tumor (NET)
7.3.1. Overview
7.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
7.4. Others
7.4.1. Overview
7.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
8. SOMATOSTATIN ANALOGS MARKET– BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. Overview
8.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
8.2.3. U.S.
8.2.3.1. Overview
8.2.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
8.2.4. Canada
8.2.4.1. Overview
8.2.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
8.3. Europe
8.3.1. Overview
8.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
8.3.3. France
8.3.3.1. Overview
8.3.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
8.3.4. Germany
8.3.4.1. Overview
8.3.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
8.3.5. Rest of Europe
8.3.5.1. Overview
8.3.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
8.4. Asia Pacific (APAC)
8.4.1. Overview
8.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
8.4.3. China
8.4.3.1. Overview
8.4.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
8.4.4. India
8.4.4.1. Overview
8.4.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
8.4.5. Rest of APAC
8.4.5.1. Overview
8.4.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
8.5. Rest of the World
8.5.1. Overview
8.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
8.5.3. Latin America
8.5.3.1. Overview
8.5.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
8.5.4. Middle East and Africa
8.5.4.1. Overview
8.5.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
9. KEY VENDOR ANALYSIS
9.1. Novartis
9.1.1. Company Overview
9.1.2. SWOT Analysis
9.1.3. Key Developments
9.2. Peptron
9.2.1. Company Overview
9.2.2. SWOT Analysis
9.2.3. Key Developments
9.3. Chiasma, Inc.
9.3.1. Company Overview
9.3.2. SWOT Analysis
9.3.3. Key Developments
9.4. IPSEN Biopharmaceuticals, Inc.
9.4.1. Company Overview
9.4.2. SWOT Analysis
9.4.3. Key Developments
9.5. Sun Pharma
9.5.1. Company Overview
9.5.2. SWOT Analysis
9.5.3. Key Developments
10. 360 DEGREE ANALYSTVIEW
11. APPENDIX
11.1. Research Methodology
11.2. Abbreviations
11.3. Disclaimer
11.4. Contact Us
List of Tables
Table 1 List of Acronyms
Table 2 Key Market Facts, 2014 – 2025
Table 3 Market Drivers: Impact Analysis
Table 4 Market Restraint: Impact Analysis
Table 5 Market Opportunity: Impact Analysis
Table 6 PEST Analysis
Table 7 Porter’s Five Forces Analysis
Table 8 Company Market Share Analysis
Table 9 Global Somatostatin Analogs Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
Table 10 Somatostatin Analogs Market, by Analog Type, 2014 – 2025 (USD Billion)
Table 11 Somatostatin Analogs Market, by Indication, 2014 – 2025 (USD Billion)
Table 12 Somatostatin Analogs Market, by Geography, 2014 – 2025 (USD Billion)
Table 13 North America Somatostatin Analogs Market, 2014 – 2025 (USD Billion)
Table 14 U.S. Somatostatin Analogs Market, 2014 – 2025 (USD Billion)
Table 15 Canada Somatostatin Analogs Market, 2014 – 2025 (USD Billion)
Table 16 Europe Somatostatin Analogs Market, 2014 – 2025 (USD Billion)
Table 17 France Somatostatin Analogs Market, 2014 – 2025 (USD Billion)
Table 18 Germany Somatostatin Analogs Market, 2014 – 2025 (USD Billion)
Table 19 Asia Pacific Somatostatin Analogs Market, 2014 – 2025 (USD Billion)
Table 20 China Somatostatin Analogs Market, 2014 – 2025 (USD Billion)
Table 21 India Somatostatin Analogs Market, 2014 – 2025 (USD Billion)
Table 22 Latin America Somatostatin Analogs Market, 2014 – 2025 (USD Billion)
Table 23 MEA Somatostatin Analogs Market, 2014 – 2025 (USD Billion)
List of Figures
Figure 1 Research Methodology
Figure 2 Research Process Flow Chart
Figure 3 Comparative Analysis, by Geography, 2016-2025 (Value %)
Figure 4 Value Chain Analysis
Figure 5 Somatostatin Analogs Market, by Analog Type, 2014 – 2025 (USD Billion)
Figure 6 Somatostatin Analogs Market, by Indication, 2014 – 2025 (USD Billion)
Figure 7 Somatostatin Analogs Market, by Geography, 2014 – 2025 (USD Billion)
